Royal Bank of Canada Raises Holdings in Ralliant Corporation $RAL

Royal Bank of Canada increased its stake in shares of Ralliant Corporation (NYSE:RAL) by 175.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,251 shares of the company’s stock after acquiring an additional 32,024 shares during the period. Royal Bank of Canada’s holdings in Ralliant were worth $2,091,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Cetera Investment Advisers purchased a new stake in Ralliant in the 2nd quarter worth approximately $700,000. Russell Investments Group Ltd. purchased a new position in shares of Ralliant during the 2nd quarter valued at approximately $1,465,000. EverSource Wealth Advisors LLC purchased a new position in shares of Ralliant during the 2nd quarter valued at approximately $39,000. First Trust Advisors LP acquired a new position in shares of Ralliant in the 2nd quarter valued at $2,013,000. Finally, Federated Hermes Inc. purchased a new stake in Ralliant during the second quarter worth $326,000.

Ralliant Trading Down 0.4%

RAL opened at $72.03 on Tuesday. The firm has a market capitalization of $7.97 billion, a price-to-earnings ratio of -6.64, a price-to-earnings-growth ratio of 2.69 and a beta of 1.61. The company’s 50 day simple moving average is $68.82 and its two-hundred day simple moving average is $55.58. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts expect that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s dividend payout ratio is presently -1.84%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on RAL. TD Cowen lifted their price objective on shares of Ralliant from $70.00 to $80.00 and gave the company a “buy” rating in a report on Friday, July 31st. Royal Bank Of Canada lifted their price target on Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. Wall Street Zen downgraded Ralliant from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 11th. Finally, Oppenheimer boosted their price objective on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.